(Q43062432)

13 November 2017

COX 2 inhibitors, traditional NSAIDs, and the heart (English)

1 reference

13 November 2017

2

1 reference

13 November 2017

1

Peter Jüni

1 reference

13 November 2017

Matthias Egger

3

1 reference

PMCID

558270

13 November 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

13 November 2017

1 reference

13 November 2017

330

1 reference

13 November 2017

7504

1 reference

13 November 2017

1342-1343

1 reference

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

13 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Better reporting of harms in randomized trials: an extension of the CONSORT statement

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Lessons from the withdrawal of rofecoxib

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=558270

Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested

15 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15947376

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/BMJ.330.7504.1342

1 reference

13 November 2017

1 reference

13 November 2017

1 reference

PMCID

558270